In a blog post today, AHA Executive Vice President Tom Nickels takes issue with a recent Axios article comparing hospital prices to drug prices. “Comparing hospital prices to drug prices is absurd,” Nickels writes. “And although the article claims to be about prices, the chart actually shows National Health Expenditure spending numbers, not prices. Despite that, hospital spending has grown at a slower rate than drug spending over the time period displayed in the chart. And as a percentage of the NHE, hospital care actually declined from 42.7% in 1980 to 34% in 2016, compared to retail prescription drug spending, which doubled as a share of total national health expenditures. … Hospital prices have also grown more slowly than drug prices, despite rising input costs. Hospital price growth as measured by the Producer Price Index, has remained under 2% for each of the last four years. Even before that, since 2008, hospital prices had an average annual growth rate of 2%. In comparison, the overall price of medical care had an average annual growth rate of 3%, while drug prices had a significantly higher average annual growth rate of 5.6% for that same time period.”

Headline
The AHA’s American Society for Health Care Engineering announced July 27 that Geisinger is the winner of its 2026 Excellence in Health Care Facility Management…
Headline
The U.S. District Court for the District of Maryland July 16 enjoined eight provisions from the Centers for Medicare & Medicaid Services’ 2027 notice of…
Headline
The AHA’s American Society for Health Care Engineering will host the Health Care Facilities Innovation Conference in Minneapolis from Aug. 2-5. The conference…
Headline
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation…
Headline
The inaugural Hospital Capacity Management Leadership Forum, tailored to hospital and health system leaders responsible for hospital flow, will be held July 11…
Headline
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…